Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 3/20 | 0.39 |
| ▸ | PER2 | O15055 | 2/20 | 0.38 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | USP19 | O94966 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24880100 | 0.83 | TSHR (0.55) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL15110556 | 0.81 | GLA (0.50) | HSD17B10POLBGAASMN1; SMN2PRMT5 | |
| SCHEMBL2824102 | 0.79 | GAA (0.41) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL24879866 | 0.79 | SMN1; SMN2 (0.41) | HSD17B10POLBGAASMN1; SMN2PRMT5 | |
| SCHEMBL28056768 | 0.79 | GLA (0.43) | HSD17B10POLBGAASMN1; SMN2PRMT5 | |
| SCHEMBL8741576 | 0.78 | — | — | |
| SCHEMBL2954981 | 0.78 | GLA (0.42) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL18287198 | 0.76 | POLB (0.40) | POLBGAASMN1; SMN2PRMT5WDR77 | |
| SCHEMBL2825160 | 0.76 | TSHR (0.45) | POLBGAASMN1; SMN2KMT2ATSHR | |
| SCHEMBL21823015 | 0.75 | KDM4E (0.38) | HSD17B10POLBGAASMN1; SMN2PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4630406-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024121046-A1 | AMIDE COMPOUNDS AS ACTIVATORS OF THE POTASSIUM CHANNELS KV7.2/KV7.3 USEFUL IN THE TREATMENT OF CNS AND PNS DISORDERS | ANGELINI PHARMA S.P.A. (IT) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024099435-A1 | TEAD INHIBITOR | 武汉人福创新药物研发中心有限公司 | 2024-05-16 | — | — | WO | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | CARMOT THERAPEUTICS, INC. | 2023-11-09 | — | — | US | disclosed |
| US-11535660-B1 | Modulators of G-protein coupled receptors | Cannot Therapeutics, Inc. (US) | 2022-12-27 | — | — | US | disclosed |
| US-20210284627-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-09-16 | — | — | US | disclosed |
| US-20210284627-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2021-09-16 | — | — | US | disclosed |
| EP-3766877-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-20 | — | — | EP | disclosed |
| EP-3766877-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-20 | — | — | EP | disclosed |
| EP-2505586-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-10-03 | — | — | EP | disclosed |
| EP-2505586-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2012-10-03 | — | — | EP | disclosed |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2011-12-15 | — | — | US | disclosed |
| CN-101287738-B | Imidazo benzodiazepine derivatives | HOFFMANN LA ROCHE | 2011-08-10 | — | — | CN | disclosed |
| WO-2011065402-A1 | INDOLE COMPOUND AND PHARMACEUTICAL USE THEREOF | 日本たばこ産業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| CN-101287738-A | Imidazo benzodiazepine derivatives | HOFFMANN LA ROCHE (CH) | 2008-10-15 | — | — | CN | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357347-A1 | MODULATORS OF G-PROTEIN COUPLED RECEPTORS | GIPR, GLP1R, GCGR | HSD17B10 3693/4885POLB 4729/4885GAA 1526/4885 |
| US-11535660-B1 | Modulators of G-protein coupled receptors | GIPR, GLP1R, GCGR | HSD17B10 3804/4885POLB 4782/4885GAA 1536/4885 |
| US-20210284627-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | HSD17B10 1181/4885POLB 4698/4885GAA 2316/4885 |
| US-20110306599-A1 | INDOLE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | IDO1, IDO2, INMT | HSD17B10 1181/4885POLB 4698/4885GAA 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.